Current Status of Apotex's Ruxolitinib ANDA
No specific FDA approval decision date is set for Apotex's abbreviated new drug application (ANDA) for ruxolitinib, the generic version of Incyte/BMS's Jakafi. The ANDA (205486) remains pending with a Paragraph IV certification, triggering ongoing patent litigation.[1][2]
What Paragraph IV Means Here
Apotex filed under Paragraph IV, challenging patents listed for Jakafi (ruxolitinib phosphate) in the FDA's Orange Book. This requires FDA tentative approval before final resolution, but no tentative approval date is public. Litigation with Incyte/BMS started in 2022 in Delaware federal court.[2]
Patent Expiry and Litigation Timeline
Key Jakafi patents expire in 2027 (U.S. Patent 9,919,078) and extend to 2031 with pediatric exclusivity, though challenges could shorten this.[3] Court decisions or settlements will dictate ANDA approval timing. No trial date is scheduled yet; cases often take 2-3 years.
Other Generic Challengers and Market Impact
Apotex is among filers like Cipla, Dr. Reddy's, and MSN, all in similar Paragraph IV suits. First generic entry likely post-2027 unless courts invalidate patents earlier. Check FDA's ANDA status database for updates.[1]
How to Track FDA Decisions
Search FDA's Approved Drug Products database or Paragraph IV Patent Certifications list for changes. DrugPatentWatch tracks litigation and expiry risks.[2][3]
[1]: FDA Orange Book
[2]: DrugPatentWatch - Ruxolitinib Litigation
[3]: DrugPatentWatch - Jakafi Patents